Multicenter RCT of SSRF in Non Flail Patients (CWISNONFLAIL)
Primary Purpose
Rib Fracture Multiple
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Operative
Sponsored by
About this trial
This is an interventional other trial for Rib Fracture Multiple
Eligibility Criteria
Inclusion Criteria:
- Hospitalization with ≥ 3 severely displaced (≥ 50% of rib width) acute rib fractures.
Two or more of the following pulmonary physiologic derangements (at the time of consideration for enrollment and after best medical therapy).
- Respiratory rate > 20 breaths per minute
- Incentive spirometry < 50% predicted (appendix D)
- Numeric pain score > 5
- Poor cough (as documented by respiratory therapist)
- Surgery anticipated < 72 hours from injury
Exclusion Criteria:
- Age < 18 years or ≥ 80 years
- Flail chest: either radiographic or clinical. Radiographic flail chest is defined on CT chest as ≥ 2 ribs each fractured in ≥ 2 places. Clinical flail is defined as visualization of a segment of chest wall with paradoxical motion on physical exam.
- Moderate or severe traumatic brain injury (GCS at the time of consideration for enrollment < 12)
- Intubation
- Severe pulmonary contusion, defined as Blunt Pulmonary Contusion 18 (BPC18) score > 12 [19].
- Prior or expected emergency exploratory laparotomy during this admission.
- Prior or expected emergency thoracotomy during this admission.
- Prior or expected emergency craniotomy during this admission.
- Spinal cord injury
- Pelvic fracture that has required, or is expected to require, operative intervention during this admission.
- The patient was unable to accomplish activities of daily living independently prior to injury (e.g., dressing, bathing, prepearing meals).
- Pregnancy.
- Incarceration.
Sites / Locations
- Denver Health Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Operative
Non-operative
Arm Description
Patients in the operative arm will undergo best medical management, in addition to surgical stabilization of their displaced rib fractures within 72 hours of admission to the hospital.
Patients in the non operative arm will undergo best medical management of their displaced rib fractures.
Outcomes
Primary Outcome Measures
Numeric Pain Score
Patient self-reported pain score on an 11 point scale scale ranging from 0-10; 0 being "no pain" to 10 "the worst pain imaginable".
Secondary Outcome Measures
Length of Stay
Patient length of stay in hospital and/or ICU.
Daily Narcotic Use
Total standardized narcotic equivalents per day, which is calculated using an equil-analgesic scale:
Narcotic Dose Unit Route Hydromorphone 1.5 mg IV Hydromorphone 7.5 mg PO Fentanyl 100 mcg IV Morphine 10 mg IV Morphine 30 mg PO Oxycodone 20 mg PO Hydrocodone 30 mg PO
*IV, intravenous; mcg, micrograms; mg, milligrams; PO, per oral
Incentive Spirometry
The maximum volume (ml) of inspired air through a handheld device called an incentive spirometer. Best value of 3 attempts is recorded. The value of the inspired volume is normalized for patients age, sex, and height and in measured in the percent predicted for that particular individual.
Pulmonary Function Testing
Forced expired volume in 1 second, measured in pulmonary function lab
Number of Patients With Pneumonia
CDC definition of nosocomial pneumonia
Days of Ventilator-dependent Respiratory Failure
Mechanical ventilation for > 24 hours at any time during index hospitalization
Chest Wall Specific Quality of Life Questionnaire
An 8 question, validated quality of life (QoL) questionnaire administered at outpatient, clinic follow-up encounters after discharge from the index admission. Minimum score is 0 and indicates the worst outcome of QoL while maximum score is 55, which indicates the highest outcome of QoL.
Full Information
NCT ID
NCT03221595
First Posted
July 12, 2017
Last Updated
April 9, 2021
Sponsor
Denver Health and Hospital Authority
Collaborators
DePuy Synthes
1. Study Identification
Unique Protocol Identification Number
NCT03221595
Brief Title
Multicenter RCT of SSRF in Non Flail Patients
Acronym
CWISNONFLAIL
Official Title
A Multicenter, Randomized Controlled Trial of Surgical Stabilization of Rib Fractures in Patients With Severe, Non-flail Fracture Patterns
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Completed
Study Start Date
January 2, 2018 (Actual)
Primary Completion Date
October 22, 2019 (Actual)
Study Completion Date
January 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Denver Health and Hospital Authority
Collaborators
DePuy Synthes
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study evaluates the efficacy of surgical stabilization of rib fractures, as compared to best medical management, for patients with multiple, displaced rib fractures.
Half of patients will be randomized to surgery (in addition to best medical management), whereas the other half will be randomized to medical therapy only.
The primary outcome will be the subjects overall quality of life measured at two months following injury.
Detailed Description
Rib fracture are the most common serious injury following blunt trauma, and occur in approximately 10% of trauma patients [1]. Despite improvements in the care of rib fracture patients, outcomes remain poor and have not changed substantially over the last 15 years [2]. Poor outcomes resulting from serious rib fractures include both acute complications (e.g., pneumonia, prolonged mechanical ventilation, and death) and chronic disability (e.g., pain, dyspnea, and loss of productivity).
Over the last 10 years, surgical stabilization of rib fractures (SSRF) has emerged as a promising technology for the management of patients with severe chest wall injuries [3]. Conceptually, SSRF applies the fundamental orthopedic principles of reduction and fixation to rib fractures, restoring chest wall stability and minimizing pain with respiration, splinting, and secretion accumulation. The advent of muscle-sparring [4] and even minimally-invasive surgical techniques [5], as well as a relatively low complication rate [6], has improved the appeal of this operation.
To date, three randomized clinical trials (RCTs) [7-9] and three meta-analyses of these and other trials [10-12] have limited their scope to patients with flail chest, a specific clinical diagnosis characterized by paradoxical motion of a portion of the chest wall due to fractures of two or more ribs in at least two places. Flail chest represents the most severe form of chest wall injury, with an associated, very high morbidity and mortality. Each of the aforementioned RCTs, as well as multiple prospective, non-randomized investigations [13, 14], have found a benefit to SSRF as compared to best medical management in this patient population. Accordingly, expert consensus statements have recommended this operation in this subset of patients [3, 15].
Based upon the favorable reported efficacy of SSRF in patients with flail chest, many surgeons have broadened indications to patients with severe, non-flail rib fracture patterns, most commonly ≥ 3 severely displaced fractures. Although these injuries differ anatomically from flail chest, many of the same pathophysiologic principles are at work: namely, painful motion at the fracture sites cause respiratory compromise, bony bridging [16], and risk of subsequent non-union, chronic pain, and restrictive lung disease. However, it is not clear if stabilization of these fractures confers the same benefits as in the case of flail chest. This lack of efficacy data has been recognized in recent guidelines, which were unable to recommend SSRF for non-flail fracture patterns pending further data. Furthermore, long term quality of life data for both flail and non-flail fracture patterns managed with SSRF are not available.
The use of SSRF is increasing exponentially. Somewhat alarmingly, nearly one half of the procedures were performed in patients without flail chest [17]. A combination of the favorable results observed for SSRD in flail chest, the increasing prevalence of SSRF for non flail-chest, and the lack of quality evidence to support this operation in this patient population, lead to the design of the current RCT. The objective of this trial is to investigate the efficacy of SSRF, as compared to non-operative management, for hospitalized patients with specific, non-flail, severe rib fractures, and within expert, high volume centers that participate in the Chest Wall Injury Society. The investigators hypothesize that SSRF, as compared to standardized medical management, improves pain control, pulmonary function, risk of complications, and quality of life among patients with severe, non-flail chest fracture patterns.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rib Fracture Multiple
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
randomized, controlled trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
110 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Operative
Arm Type
Experimental
Arm Description
Patients in the operative arm will undergo best medical management, in addition to surgical stabilization of their displaced rib fractures within 72 hours of admission to the hospital.
Arm Title
Non-operative
Arm Type
No Intervention
Arm Description
Patients in the non operative arm will undergo best medical management of their displaced rib fractures.
Intervention Type
Device
Intervention Name(s)
Operative
Other Intervention Name(s)
Surgical stabilization of rib fractures, rib plating
Intervention Description
This operation involves reducing and providing rigid fixation of displaced rib fractures with permanent plates or splints
Primary Outcome Measure Information:
Title
Numeric Pain Score
Description
Patient self-reported pain score on an 11 point scale scale ranging from 0-10; 0 being "no pain" to 10 "the worst pain imaginable".
Time Frame
Hospital days 1-7, day of discharge (an average of 1 week) and at 2, 4 and 8 weeks following discharge from hospital.
Secondary Outcome Measure Information:
Title
Length of Stay
Description
Patient length of stay in hospital and/or ICU.
Time Frame
2 months after injury
Title
Daily Narcotic Use
Description
Total standardized narcotic equivalents per day, which is calculated using an equil-analgesic scale:
Narcotic Dose Unit Route Hydromorphone 1.5 mg IV Hydromorphone 7.5 mg PO Fentanyl 100 mcg IV Morphine 10 mg IV Morphine 30 mg PO Oxycodone 20 mg PO Hydrocodone 30 mg PO
*IV, intravenous; mcg, micrograms; mg, milligrams; PO, per oral
Time Frame
Inpatient: occurred daily at 10 AM while the patient was hospitalized. Post-discharge: occurred at outpatient clinic follow-up encounter that occurred at 2, 4, and 8 weeks post discharge.
Title
Incentive Spirometry
Description
The maximum volume (ml) of inspired air through a handheld device called an incentive spirometer. Best value of 3 attempts is recorded. The value of the inspired volume is normalized for patients age, sex, and height and in measured in the percent predicted for that particular individual.
Time Frame
Inpatient: occurred daily at 10 AM while the patient was hospitalized. Post-discharge: occurred at outpatient clinic follow-up encounter that occurred at 2, 4, and 8 weeks post discharge.
Title
Pulmonary Function Testing
Description
Forced expired volume in 1 second, measured in pulmonary function lab
Time Frame
once, at first follow-up, outpatient, clinic visit, which occurred at 2 weeks post discharge.
Title
Number of Patients With Pneumonia
Description
CDC definition of nosocomial pneumonia
Time Frame
Study participants were followed up to 2 months after index admission date.
Title
Days of Ventilator-dependent Respiratory Failure
Description
Mechanical ventilation for > 24 hours at any time during index hospitalization
Time Frame
Study participants were followed up to 2 months after index admission date.
Title
Chest Wall Specific Quality of Life Questionnaire
Description
An 8 question, validated quality of life (QoL) questionnaire administered at outpatient, clinic follow-up encounters after discharge from the index admission. Minimum score is 0 and indicates the worst outcome of QoL while maximum score is 55, which indicates the highest outcome of QoL.
Time Frame
2, 4 and 8 weeks after discharge from the index admission
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Hospitalization with ≥ 3 severely displaced (≥ 50% of rib width) acute rib fractures.
Two or more of the following pulmonary physiologic derangements (at the time of consideration for enrollment and after best medical therapy).
Respiratory rate > 20 breaths per minute
Incentive spirometry < 50% predicted (appendix D)
Numeric pain score > 5
Poor cough (as documented by respiratory therapist)
Surgery anticipated < 72 hours from injury
Exclusion Criteria:
Age < 18 years or ≥ 80 years
Flail chest: either radiographic or clinical. Radiographic flail chest is defined on CT chest as ≥ 2 ribs each fractured in ≥ 2 places. Clinical flail is defined as visualization of a segment of chest wall with paradoxical motion on physical exam.
Moderate or severe traumatic brain injury (GCS at the time of consideration for enrollment < 12)
Intubation
Severe pulmonary contusion, defined as Blunt Pulmonary Contusion 18 (BPC18) score > 12 [19].
Prior or expected emergency exploratory laparotomy during this admission.
Prior or expected emergency thoracotomy during this admission.
Prior or expected emergency craniotomy during this admission.
Spinal cord injury
Pelvic fracture that has required, or is expected to require, operative intervention during this admission.
The patient was unable to accomplish activities of daily living independently prior to injury (e.g., dressing, bathing, prepearing meals).
Pregnancy.
Incarceration.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fredric M Pieracci, MD MPH
Organizational Affiliation
Denver Health Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Denver Health Medical Center
City
Denver
State/Province
Colorado
ZIP/Postal Code
80204
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
27912931
Citation
Pieracci FM, Majercik S, Ali-Osman F, Ang D, Doben A, Edwards JG, French B, Gasparri M, Marasco S, Minshall C, Sarani B, Tisol W, VanBoerum DH, White TW. Consensus statement: Surgical stabilization of rib fractures rib fracture colloquium clinical practice guidelines. Injury. 2017 Feb;48(2):307-321. doi: 10.1016/j.injury.2016.11.026. Epub 2016 Nov 27. No abstract available.
Results Reference
background
Learn more about this trial
Multicenter RCT of SSRF in Non Flail Patients
We'll reach out to this number within 24 hrs